Research Article
Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
Table 1
Demographic and clinical data combined with therapeutic features of patients with axSpA enrolled in our study.
| | Demographic features | |
| | Age (years) | | | Disease duration (years) | | | Females/males | 27/12 | | Clinical features | (%) | | HLA B27 + | 6/39 (15.38%) | | Psoriasis | 19/39 (48.71)% | | Radiographic SpA | 26/39 (66.66%) | | Peripheral involvement | 31/39 (79.48%) | | GI tract involvement | 0/39 (0%) | | Ocular involvement | 4/39 (10.25%) | | PPD test + | 4/39 (10.25%) | | QFT + | 4/39 (10.25%) | | Therapeutic features | (%) | | Previous anti-TNF failure | 29/39 (74.35%) | | Use of concomitant GC | 11/39 (28.20%) | | Use of concomitant DMARDs | 14/39 (35.89%) | | SCK 150/mg/injection | 17/39 (43.58%) | | SCK 300/mg/injection | 22/39 (56.41%) |
|
|
GC: glucocorticoids; GI: gastrointestinal; HLA: human leukocyte antigen; PPD: purified protein derivative; QFT: quantiFERON-TB; SCK: secukinumab; SD: standard deviation; SpA: spondyloarthritis; TNF: tumour necrosis factor.
|
